Home Stock Roche says Alzheimer's antibody gets U.S. breakthrough designation

Roche says Alzheimer’s antibody gets U.S. breakthrough designation

imageStock Markets15 minutes ago (Oct 08, 2021 12:16PM ET)

(C) Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

ZURICH (Reuters) – Roche said on Friday its gantenerumab antibody had received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease.

The Swiss pharmaceutical giant said in a statement it expected further data on an ongoing Phase III study in the second half of 2022.

Roche says Alzheimer’s antibody gets U.S. breakthrough designation

European stocks log best week in two months

European stocks log best week in two months
By Reuters – Oct 08, 2021

By Sruthi Shankar and Susan Mathew (Reuters) -European stocks ended a volatile session lower on Friday as investors digested data showing slowing jobs growth in the United States,…

Germany stocks lower at close of trade; DAX down 0.29%

Germany stocks lower at close of trade; DAX down 0.29%
By Investing.com – Oct 08, 2021

Investing.com – Germany stocks were lower after the close on Friday, as losses in the Utilities, Transportation & Logistics and Consumer & Cyclical sectors led shares lower.
At…

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

image

Our Apps

DOWNLOAD APPApp store

Investing.com

(C) 2007-2021 Fusion Media Limited. All Rights Reserved

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Subscribe here

Categories

Must Read